

## Research Article

# Survival analysis of COVID-19 versus non-COVID-19 patients requiring intensive care for acute respiratory distress syndrome: An observational retrospective study

Paulo Navas Boada<sup>1</sup>, Kevin Chamorro<sup>2</sup>, Santiago Ballaz<sup>3</sup>

<sup>1</sup> School of Biological Sciences and Engineering, Universidad Yachay Tech, <sup>2</sup> School of Mathematics and Computational Sciences, Universidad Yachay Tech, <sup>3</sup> Medical School, Universidad de Especialidades Espíritu Santo

Keywords: ARDS, Cox multivariate analysis, COVID-19, Intensive care units, Kaplan-Meier survival curve, length of stay, respiratory therapy

<https://doi.org/10.29390/001c.122402>

---

## Canadian Journal of Respiratory Therapy

Vol. 60, 2024

---

### Abstract

#### Background/Aim

This study analyzed clinical factors impacting the survival of COVID-19 patients with acute respiratory distress syndrome, or ARDS (CARDS) to ICU compared to non-COVID-19 ARDS patients.

#### Methods

Clinical variables from 1,008 CARDS cases and 332 ARDS cases were computed using learning algorithms. The multivariable Cox proportional hazards regression models with the enter method evaluated risk factors and ICU mortality relationships. The survival analysis was completed with Kaplan-Meier and the log-rank tests.

#### Results

A Random Forest model revealed that mechanical ventilation-related factors, oxygenation, blood pH, superinfection, shock, and ICU length of stay have the greatest effects on ICU survival. According to a multivariate Cox model, reintubation and a high-flow nasal cannula were essential for survival in CARDS patients during the ICU stay. The length of stay in the ICU diminishes in patients older than 45 years, regardless of the source of ARDS.

#### Conclusion

This study gives recommendations for the respiratory care of ARDS in COVID-19 patients.

## INTRODUCTION

Acute respiratory distress syndrome, or ARDS, is an important complication of COVID-19<sup>1</sup> and one of the main reasons for ICU admission of patients afflicted with the illness. ARDS is a life-threatening lung condition that is characterized by extensive inflammation, lung damage, and pulmonary edema, which lower oxygen levels and cause breathing difficulties.<sup>2</sup> Some evidence has questioned whether COVID-19-associated ARDS (CARDS) and typical ARDS are truly different,<sup>3-5</sup> despite many clinical characteristics appearing similar to those of the “non-COVID-19” ARDS.<sup>6-9</sup> The potential distinguishing features of SARS-CoV-2-induced ARDS and suggested management strategies for patients with severe COVID-19 are hotly contested topics.<sup>10,11</sup> One reason for the controversy is the variability of clinical characteristics among COVID-19 patients with

ARDS. The two phenotypes of CARDS are typical ARDS (“H-type”), which is characterized by reduced lung volume, decreased lung compliance, and unmatched ventilation-perfusion ratio, and a distinct condition known as “silent hypoxia,” which is linked to nearly normal lung compliance and progressive respiratory distress.<sup>12</sup> Another one is its distinct pathophysiology,<sup>13,14</sup> which may alter current evidence-based management strategies for CARDS.<sup>15-19</sup>

Glucocorticoids are used to reduce mortality in patients with CARDS who are admitted to ICU<sup>20</sup>; nonetheless, there are substantial problems with their accurate clinical treatment and survival.<sup>21,22</sup> Furthermore, when the COVID-19 pandemic began, CARDS patients were also treated with antiretrovirals like lopinavir and ritonavir in compliance with the WHO guidelines. However, these guidelines were adjusted as more information about their safety and efficacy was available. In this investigation, we particularly concentrated on non-pharmacological approaches to ad-

dress ARDS. At a glance, literature searches yield results that are partly conflicting regarding the precise clinical management of CARDS patients admitted to ICU.<sup>4,6,23-26</sup> Therefore, the purpose of this study was to use advanced data mining techniques in conjunction with survival analysis to do a retrospective, observational analysis of the clinically relevant parameters impacting the survival of CARDS to ICU compared to non-COVID-19, other-etiology ARDS patients.

## METHODS

### SELECTION AND CLASSIFICATION OF COVID-19 AND NON-COVID-19 ARDS CASES

Data from patients' electronic medical records of the Guasmo Sur General Hospital (Guayaquil, ECUADOR) were collected and reviewed by physicians trained in critical care. The study comprised 1,341 consecutive patients with low-to-moderate and severe ARDS (i.e., alveolar pressure / inspired oxygen fraction (PaFi) less than 300) admitted in the ICU from February 2020 to August 2022. The Berlin definition<sup>2</sup> was used to diagnose ARDS as the primary reason for ICU admission. ARDS-ill patients were included in either the CARDS cohort (patients with a positive RT-qPCR test for SARS-CoV-2) or in the typical ARDS cohort (patients with a negative RT-qPCR test for SARS-CoV-2) based on the CDC 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel in upper and lower respiratory specimens. Approximately 95% of the patients received corticoid treatment.

### DATA PROCESSING AND FEATURE SELECTION

A dataset containing a variety of clinical variables and outcomes was obtained from the hospital's digital records. The initial step in data processing entailed performing an exploratory analysis to determine the various data categories, the COVID-19 patient's status of discharge, and a distribution of features (a comprehensive list is supplied in Supplementary Material 1). Further processing addressed missing values via imputation (if any), scaled the numerical variables, and encoded the categorical features to ensure interoperability with the machine learning techniques implemented in Python programming language.<sup>27</sup>

### STATISTICS

Statistical analysis of the data was performed using Rstudio free software environment (<https://www.r-project.org/>). While Welch's *t*-test was used to evaluate quantitative data (given as mean  $\pm$  SD), the Chi-square test was utilized to analyze categorical data. The multivariable Cox proportional hazards regression models with the enter method were used to evaluate the relationship between risk factors and ICU mortality. The Kaplan-Meier survival estimates and the log-rank test were used to analyze sex- and age-dependent effects in terms of survival. Alpha threshold was always set at 0.05.

## ETHICS

On December 4<sup>th</sup>, 2023, the Manabí Tech University Ethics Committee approved this study (Ref# CEISH\_UTM\_EXT\_23-11-29\_SJB), and each subject provided written informed consent. The ICU medical director at the Guasmo Sur General Hospital gave the authorization to download the information from the digital clinical records system. The Declaration of Helsinki was followed when conducting the study.

## RESULTS

### NATURE AND DISTRIBUTION OF THE SAMPLE

A total of 1,340 cases of ARDS patients were in intensive care; 716 male patients (53.43%) and 624 female patients (46.57%) were included. After that, the sample was split into two cohorts: the non-COVID-19 ARDS cohort (332 ARDS cases including 158 males (47.59%) and 174 females (52.41%)) and the COVID-19-associated ARDS cohort (1008 CARDS patients including 558 males (55.36%) and 450 females (44.64%)). The primary causes of ARDS that were not associated with COVID-19 were septic shock (20.5%), obstetric emergencies (14.7%), abdominal trauma (11.7%), pneumonia (10.3%), and pancreatitis (4.4%). Compared to normal ARDS cases ( $n=91$ , 27.41%) ( $\chi^2=7.26$ ,  $p < 0.01$ ), the death rate among CARDS cases ( $n=508$ , 50.40%) was substantially greater. More men ( $n=293$ , 57.68%) died in the CARDS cohort at a higher rate than women ( $n=215$ , 42.32%), but the differences were not statistically significant ( $\chi^2=2.05$ ,  $p=0.153$ ). Males ( $n=54$ , 59.34%) were considerably more affected by mortality in the ARDS group than females ( $n=37$ , 40.66%) ( $\chi^2=6.31$ ,  $p < 0.05$ ). Patients with CARDS and ARDS had averaged ages of  $54.1 \pm 15.26$  years and  $41.06 \pm 18.11$  years, respectively. In both the ARDS cohort (survivors:  $38.19 \pm 17.22$  years and non-survivors:  $48.67 \pm 18.30$  years;  $t(153)=-4.73$ ,  $p < 0.001$ ) and the CARDS cohort (survivors:  $49.6 \pm 15.33$  years and non-survivors:  $58.53 \pm 13.83$  years;  $t(992)=-9.70$ ,  $p < 0.001$ ), the death rate rose with age.

### FEATURE SELECTION


The evaluation metrics of the algorithms when classifying patient's survival are shown in [Table 1](#). Despite slight overfitting, the tuned Random Forest model proved to be the most effective across most metrics in predicting mortality in ARDS patients submitted to intensive care, showing a training and test precision of 98% and 86%, respectively. A Random Forest model for feature selection and dimensionality reduction helped identify crucial predictors for ICU mortality, including mechanical ventilation-related factors (FiO<sub>2</sub>, PaO<sub>2</sub>/FiO<sub>2</sub>), pO<sub>2</sub>, age, superinfection, shock, blood pH, and ICU length of stay ([Figure 1](#)).

### SURVIVAL ANALYSIS AND ASSOCIATED RISK FACTORS

Risk factors for mortality due to the ICU length of stay were separately analyzed in CARDS and ARDS cohorts using

**Table 1. Algorithm evaluation metrics. Metric values with performance parameters during the training and test validations.**

Model	Training Accuracy	Test Accuracy	Training Precision	Test Precision	Training Recall	Test Recall	Training F1 Score	Test F1 Score	Training ROC AUC	Test ROC AUC
Logistic Regression	0.86	0.78	0.84	0.77	0.84	0.71	0.84	0.74	0.93	0.88
SVM	0.83	0.78	0.83	0.78	0.78	0.70	0.80	0.74	0.90	0.88
Decision Tree	0.96	0.79	0.98	0.81	0.91	0.69	0.95	0.75	0.99	0.75
Random Forest	0.98	0.86	0.99	0.86	0.97	0.8	0.98	0.83	0.99	0.92
Neural Network	0.99	0.82	1	0.80	0.99	0.79	0.99	0.79	1	0.89

**Figure 1. Heat map showing the topmost significant features predicting ICU mortality (condition of discharge) in patients suffering from ARDS.**

Abbreviations: CVC, central venous catheter.

the Cox proportional hazards regression model. Table 2 together shows the outcomes of the Cox multivariate analysis in CARDS and ARDS cohorts. Even if most variables were statistically associated with mortality during the ICU stay, their hazard ratios were close to 1 and, therefore, irrelevant from a clinical perspective. Risk factors affecting ICU survival varied across CARDS and ARDS cohorts. On the one hand, high-flow nasal cannula ( $t = -6.57, p < 0.001$ ) and reintubation ( $t = -4.2, p < 0.001$ ) significantly increased ICU survival of CARDS patients. On the other hand, mechanical ventilation ( $t = 3.36, p < 0.001$ ) and superinfection ( $t = 2.90, p < 0.001$ ) were significantly associated with the premature death of ARDS patients during their ICU stay (Table 2). Survival showed sex-dependent differences only in the ARDS cohort. Women with ARDS had a lower average risk for mortality due to the ICU length of stay compared to

their male counterparts ( $\chi^2 = 6.31; p < 0.01$ ) (Figure 2). Regarding the influence of age (Figure 3), as expected, patients over 45 years old had less chance of surviving an ICU stay (CARDS group:  $\chi^2 = 68.53; p < 0.0001$ ; ARDS group:  $\chi^2 = 22.62; p < 0.001$ ).

## DISCUSSION

The key finding of this study was that, in both cohorts, the management of ARDS with respiratory treatments had a varied impact on ICU survival. The CARDS cohort's survival was greatly dependent on the delivery of a high-flow nasal cannula and reintubation in particular. Due to the length of ICU stay, mechanical ventilation and consequent superinfections were risk factors for death in the typical ARDS cohort.


Volume-Controlled Ventilation (VCV) and Pressure-Controlled Ventilation (PCV) were the most commonly utilized ventilator modes for treating CARDS and ARDS, respectively, based on our database. These modes make it possible to precisely modify respiratory parameters, which helps with lung protection and ventilator management. Furthermore, non-traditional modes, including Airway Pressure Release Ventilation (APRV) and Pressure-Regulated Volume Control (PRVC), were used, showing effectiveness in minimizing ventilator-induced lung damage and optimizing oxygenation. By lowering alveolar distension pressure and raising the ventilation-perfusion ratio, these non-conventional methods hoped to increase survival rates and lessen pulmonary consequences in ARDS patients.<sup>28</sup>

Our database also showed that different approaches were used to manage Positive End Expiratory pressure (PEEP) titration and alveolar recruitment. An inflation-deflation index was performed before alveolar recruitment maneuvers (ARM) to evaluate the lung's resistance to pressure fluctuations and ascertain the maneuver's efficacy. Particular methods for recruiting alveoli were used, such as ARM, which involves temporarily raising airway pressure to expand collapsed alveoli—furthermore, PEEP changes based on the patient's hemodynamic response and oxygenation. By reducing the danger of barotrauma and volutrauma and maximizing the benefits of alveolar recruitment, these measures were intended to improve lung protection and survival in patients with ADRS.<sup>28</sup> The patient was success-


**Table 2. Multivariate Cox proportional hazards regression analysis (adjusted HR) of clinical factors associated with ICU mortality in ARDS patients.**

Clinical variable	CARDS HR(IC95%)	p value*	ARDS HR(IC95%)	p value*
MV	N/A	ns	4.95(1.95-12.6)	<0.001
MV days	0.836(0.813-0.859)	<0.001	0.854(0.791- 0.903)	<0.001
HFNC days	0.878(0.844-0.913)	<0.001	N/A	ns
Re-intubation	0.485(0.346-0.680)	<0.001	N/A	ns
pCO <sub>2</sub> (d-0)	1.007(1.001-1.013)	<0.05	N/A	ns
pCO <sub>2</sub> (d-7)	0.992(0.987-0.997)	<0.001	N/A	ns
FiO <sub>2</sub> (d-3)	1.016(1.007-1.025)	<0.001	N/A	ns
PaO <sub>2</sub> /FiO <sub>2</sub> (d-0)	0.995(0.993-0.997)	<0.001	0.994(0.990-0.999)	<0.05
PaO <sub>2</sub> /FiO <sub>2</sub> (d-2)	N/A	ns	1.004(1.000-1.007)	<0.05
PaO <sub>2</sub> /FiO <sub>2</sub> (d-3)	0.997(0.995-0.999)	<0.001	N/A	ns
PaO <sub>2</sub> /FiO <sub>2</sub> (d-7)	N/A	ns	0.999(0.985-0.995)	<0.001
SOFA	1.067(1.033-1.103)	<0.001	N/A	ns
Superinfection	N/A	ns	2.512(1.350-4.703)	<0.001
Age	1.013(1.006-1.020)	<0.001	1.024(1.010-1.038)	<0.001

\*Cox Proportional Hazards Regression  
Abbreviations: HFNC, High-flow nasal cannula; MV, Mechanical ventilation.



**Figure 2. Sex-dependent survival functions during ICU stay. CARDS (left) and ARDS (right).**



**Figure 3. Age-dependent survival functions during ICU stay. CARDS (left) and ARDS (right).**

fully managing spontaneous ventilation when specific criteria were fulfilled, such as PEEP equal to or less than 5 cmH<sub>2</sub>O and FiO<sub>2</sub> equal to or less than 0.4. This allowed for

the gradual reduction or withdrawal of mechanical breathing.

Using machine learning technologies made it possible to identify the most pertinent clinical features for ARDS pa-

tients requiring intensive care to forecast their mortality.<sup>29</sup> For example, the use of mechanical ventilation could increase the chance of superinfection-related death, which resulted in a decrease in the survival of the ARDS group during their ICU stay.<sup>30</sup> Remarkably, ventilator strategies related to the clinical handling of respiratory insufficiency, such as oxygenation through high-flow nasal cannula and frequent intubations, were selected for the ICU survival in the CARDS cohort,<sup>16,18,20,21</sup> rather than the most commonly used organ dysfunction scales, such as SOFA<sup>31</sup> and APACHE II.<sup>32</sup> According to Grieco et al. (2020),<sup>33</sup> the explanation could be the respiratory system's compliance, which differs between CARDS and more conventional ARDS.<sup>14,15</sup> Normalization of the early disparities in pulmonary compliance, following sufficient oxygenation and ventilator control, might be crucial for CARDS patients' survival during their ICU stay.<sup>34</sup> Respiratory failure is the most common cause for re-intubation and worse outcomes in CARDS patients.<sup>35</sup> Although re-intubation may be independently linked to CARDS mortality,<sup>36</sup> our data showed that it increased survival to ICU in CARDS patients. Consistent with earlier research, the high-flow nasal cannula (HFNC) was a crucial factor in treating moderate-to-severe CARDS, as it helped reduce mortality in these patients.<sup>37</sup> This oxygenation device offers a high flow of humidified air through a nasal cannula, greatly increasing oxygenation and reducing respiratory effort compared to mask ventilation or conventional oxygen therapy.

In addition to HFNC and re-intubation, medication may also impact CARDS. While quick results to confirm the existence of COVID-19 were not available, dexamethasone was chosen as the standard treatment for ARDS of non-infectious etiology to minimize patients' pulmonary inflammation and improve respiratory function. The ROX index was used to evaluate the monitoring and efficacy of the HFNC system. Interestingly, corticosteroids and HFNC worked well together to control ARDS and improve patient survival, which led to a notable drop in the illness-related death rate. Antivirals probably had a limited impact because they were only prescribed to CARDS patients, too, right at the start of the pandemic.

Different underlying factors can induce ARDS, which is not connected with COVID-19.<sup>1</sup> One of the main causes is pneumonia, which frequently results in primary ARDS and causes significant inflammation and destruction of the alveoli. Another important factor is trauma, especially abdominal trauma, which can result in a systemic inflammatory response that affects the lungs. Septic shock, a condition in which sepsis and extensive infection cause multiple organ failure, including the lungs, is another important component. Due to a confluence of hemodynamic and inflammatory variables, obstetric emergencies such as severe preeclampsia, amniotic fluid embolism, and postpartum hemorrhage can cause ARDS. Finally, severe secondary inflammation leading to ARDS can be caused by acute pancreatitis due to the production of inflammatory cytokines and pancreatic enzymes. Our database showed that these causes matched the trends found in cases of recorded

ARDS, demonstrating the variety and complexity of etiological elements.

In light of everything mentioned above, CARDS and ARDS may not fully respond to the same standard ventilation techniques,<sup>14,38,39</sup> even though there may be some similarities in the respiratory mechanics of both conditions.<sup>40-42</sup> Additionally, the data indicated that SARS-CoV-2 infection led to worse outcomes, consistent with previous research<sup>5,7</sup> but inconsistent with other studies.<sup>9</sup> In addition to the greater age of our CARDS sample, variations in survival over an ICU stay may be explained by minor physio-pathological changes between CARDS and ARDS that would impact respiratory efficiency.<sup>43-47</sup> Finally, the results of our investigation agree with previous research in that although hospitalized women have a lower risk of dying from COVID-19, once they are admitted to the ICU, their risk of death is comparable to that of men<sup>48</sup> (Figure 2). Age was a risk factor for ICU mortality in both cohorts (Figure 3), as previously reported.<sup>49</sup>

Although the retrospective approach and the review of records from a single institution could be seen as drawbacks, the study showed a substantial sample of patients from a COVID-19 reference hospital in Guayaquil, the largest city on Ecuador's coast. Ecuador declared Guayaquil its pandemic zero zone. During the COVID-19 outbreak, Ecuador had the highest death toll in all of South America.

## CONCLUSION

In summary, our results provide insight into specific evidence-based respiratory therapy (high-flow nasal cannula and re-intubation) for CARDS patients, for whom there are now only supportive ICU care choices available (with the exception of corticoid administration). Further research is needed to support the adjustment of ventilator and oxygenation settings in CARDS cases.

## ACKNOWLEDGEMENTS

We are grateful to the health professionals of the Hospital General Guasmo Sur in Guayaquil (Ecuador), who treated the patients and worked with us in the management of the database. We would especially like to thank Jazmin Gallego-Polo.

## AUTHORSHIP CONTRIBUTIONS

Paulo Navas-Boada was responsible for the conceptualization of the work and the resources. Kevin Chamorro made significant contributions to data curation, formal analysis, and validation. Santiago Ballaz was in charge of supervision and the writing of the original draft. All authors equally contributed to writing, review, and editing of the final manuscript.

#### FUNDING

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

#### CONFLICT OF INTEREST

The authors declare there is no conflict of interest.

#### ETHICAL APPROVAL

The Manabí Tech University Ethics Committee approved this study (Ref# CEISH\_UTM\_EXT\_23-11-29\_SJB).

#### DATA AVAILABILITY

The datasets generated analyzed during the current study are available from the corresponding author on reasonable request.

#### AI STATEMENT

The authors confirm no generative AI or AI-assisted technology was used to generate content.

Submitted: May 31, 2024 EDT, Accepted: August 07, 2024 EDT



This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CCBY-NC-4.0). View this license's legal deed at <https://creativecommons.org/licenses/by-nc/4.0> and legal code at <https://creativecommons.org/licenses/by-nc/4.0/legalcode> for more information.

## REFERENCES

1. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Int Med.* 2020;180:934-943. [doi:10.1001/jamainternmed.2020.0994](https://doi.org/10.1001/jamainternmed.2020.0994)
2. Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. *Nat Rev Dis Primers.* 2019;5:18. [doi:10.1038/s41572-019-0069-0](https://doi.org/10.1038/s41572-019-0069-0)
3. Lu S, Huang X, Liu R, et al. Comparison of COVID-19 induced respiratory failure and typical ARDS: Similarities and differences. *Front Med.* 2022;9:829771. [doi:10.3389/fmed.2022.829771](https://doi.org/10.3389/fmed.2022.829771)
4. Bernauer E, Alebrand F, Heurich M. Same but different? Comparing the epidemiology, treatments and outcomes of COVID-19 and non-COVID-19 ARDS cases in Germany using a sample of claims data from 2021 and 2019. *Viruses.* 2023;15:1324. [doi:10.3390/v15061324](https://doi.org/10.3390/v15061324)
5. Palacios-Moguel P, Esquivel-Pineda A, Flores-Andrade XA, et al. Acute respiratory distress syndrome in patients with COVID-19 vs. non-COVID-19: clinical characteristics and outcomes in a tertiary care setting in Mexico City. *BMC Pulmonary Med.* 2023;23:430. [doi:10.1186/s12890-023-02744-6](https://doi.org/10.1186/s12890-023-02744-6)
6. Brault C, Zerbib Y, Kontar L, et al. COVID-19-versus non-COVID-19-related Acute Respiratory Distress Syndrome: Differences and similarities. *Am J Respir Crit Care Med.* 2020;202:1301-1304. [doi:10.1164/rccm.202005-2025LE](https://doi.org/10.1164/rccm.202005-2025LE)
7. Ferrando C, Suarez-Sipmann F, Mellado-Artigas R, COVID-19 Spanish ICU Network, et al. Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS. *Int Care Med.* 2020;46:2200-2211. [doi:10.1007/s00134-020-06192-2](https://doi.org/10.1007/s00134-020-06192-2)
8. Di Mitri C, Arcoleo G, Mazzuca E, et al. COVID-19 and non-COVID-19 pneumonia: a comparison. *Ann Med.* 53(2021):2321-2331. [doi:10.1080/07853890.2021.2010797](https://doi.org/10.1080/07853890.2021.2010797)
9. Sjoding MW, Admon AJ, Saha AK, et al. Comparing clinical features and outcomes in mechanically ventilated patients with COVID-19 and acute respiratory distress syndrome. *Ann Am Thorac Soc.* 2021;18:1876-1885. [doi:10.1513/AnnalsATS.202008-1076OC](https://doi.org/10.1513/AnnalsATS.202008-1076OC)
10. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? *Crit Care.* 24(2020):154. [doi:10.1186/s13054-020-02880-z](https://doi.org/10.1186/s13054-020-02880-z)
11. Pu D, Zhai X, Zhou Y, et al. A narrative review of COVID-19-related acute respiratory distress syndrome (CARDS): “typical” or “atypical” ARDS? *Ann Transl Med.* 2022;10:908. [doi:10.21037/atm-22-3717](https://doi.org/10.21037/atm-22-3717)
12. Bos LDJ, Paulus F, Vlaar APJ, et al. Subphenotyping acute respiratory distress syndrome in patients with COVID-19: Consequences for ventilator management. *Ann Am Thorac Soc.* 2020;17:1161-1163. [doi:10.1513/AnnalsATS.202004-376RL](https://doi.org/10.1513/AnnalsATS.202004-376RL)
13. Grasselli G, Cattaneo E, Florio G, et al. Mechanical ventilation parameters in critically ill COVID-19 patients: a scoping review. *Crit Care.* 2021;25:115. [doi:10.1186/s13054-021-03536-2](https://doi.org/10.1186/s13054-021-03536-2)
14. Batah SS, Fabro AT. Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. *Respir Med.* 2021;176:106239. [doi:10.1016/j.rmed.2020.106239](https://doi.org/10.1016/j.rmed.2020.106239)
15. Gibson PG, Qin L, Puah SH. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. *Med J Aus.* 2020;213:54-56.e1. [doi:10.5694/mja2.50674](https://doi.org/10.5694/mja2.50674)
16. Kondili E, Makris D, Georgopoulos D, et al. COVID-19 ARDS: Points to be considered in mechanical ventilation and weaning. *J Pers Med.* 2021;11:1109. [doi:10.3390/jpm11111109](https://doi.org/10.3390/jpm11111109)
17. Sasidharan S, Singh V, Singh J, et al. COVID-19 ARDS: A Multispecialty assessment of challenges in care, review of research, and recommendations. *J Anaesthesiol Clin Pharmacol.* 2021;37:179-195. [doi:10.4103/joacp.JOACP\\_14\\_21](https://doi.org/10.4103/joacp.JOACP_14_21)
18. Zhang J, Huang X, Ding D, et al. Comparative study of acute lung injury in COVID-19 and non-COVID-19 patients. *Front Med.* 2021;8:666629. [doi:10.3389/fmed.2021.666629](https://doi.org/10.3389/fmed.2021.666629)
19. Estenssoro E, Loudet CI, Dubin A, et al. Clinical characteristics, respiratory management, and determinants of oxygenation in COVID-19 ARDS: A prospective cohort study. *J Crit Care.* 2022;71:154021. [doi:10.1016/j.jcrc.2022.154021](https://doi.org/10.1016/j.jcrc.2022.154021)
20. Bain W, Yang H, Shah FA, et al. COVID-19 versus non-COVID-19 acute respiratory distress syndrome: Comparison of demographics, physiologic parameters, inflammatory biomarkers, and clinical outcomes. *Ann Am Thorac Soc.* 2021;18:1202-1210. [doi:10.1513/AnnalsATS.202008-1026OC](https://doi.org/10.1513/AnnalsATS.202008-1026OC)

21. Pfortmueller CA, Spinetti T, Urman RD, et al. COVID-19-associated acute respiratory distress syndrome (CARDS): current knowledge on pathophysiology and ICU treatment - A narrative review. *Best Practice & Research Clin Anaesthesiol.* 2021;35:351-368. [doi:10.1016/j.bpa.2020.12.011](https://doi.org/10.1016/j.bpa.2020.12.011)
22. Robba C, Battaglini D, Ball L, et al. Ten things you need to know about intensive care unit management of mechanically ventilated patients with COVID-19. *Expert Rev Respir Med.* 2021;15:1293-1302. [doi:10.1080/17476348.2021.1906226](https://doi.org/10.1080/17476348.2021.1906226)
23. Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: Evidence and hope during the pandemic. *JAMA.* 2020;324(23):1292-1295. [doi:10.1001/jama.2020.16747](https://doi.org/10.1001/jama.2020.16747)
24. Aslan A, Aslan C, Zolbanin NM, et al. Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. *Pneumonia (Nathan).* 2021;13:14. [doi:10.1186/s41479-021-00092-9](https://doi.org/10.1186/s41479-021-00092-9)
25. Brandi N, Ciccarese F, Rimondi MR, et al. An imaging overview of COVID-19 ARDS in ICU patients and its complications: A pictorial review. *Diagnostics (Basel).* 2022;12:846. [doi:10.3390/diagnostics12040846](https://doi.org/10.3390/diagnostics12040846)
26. Yildirim S, Cinleti BA, Saygili SM, et al. The effect of driving pressures in COVID-19 ARDS: Lower may still be better as in classic ARDS. *Respir Invest.* 2021;59:628-634. [doi:10.1016/j.resinv.2021.06.002](https://doi.org/10.1016/j.resinv.2021.06.002)
27. Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: Machine learning in Python. *J Mach Learn Res.* 2011;12:2825-2830.
28. Montenegro F, Unigarro L, Paredes G, et al. Acute respiratory distress syndrome (ARDS) caused by the novel coronavirus disease (COVID-19): a practical comprehensive literature review. *Expert Rev Respir Med.* 2021;15:183-195. [doi:10.1080/17476348.2020.1820329](https://doi.org/10.1080/17476348.2020.1820329)
29. Ballaz S, Pulgar-Sánchez M, Chamorro K, et al. Scientific pertinence of developing machine learning technologies for the triage of COVID-19 patients: A bibliometric analysis via Scopus. *Inf Med Unlocked.* 2023;41:101312. [doi:10.1016/j.imu.2023.101312](https://doi.org/10.1016/j.imu.2023.101312)
30. Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. *Lancet Infect Dis.* 2013;13:665-671. [doi:10.1016/S1473-3099\(13\)70081-1](https://doi.org/10.1016/S1473-3099(13)70081-1)
31. Lavrentieva A, Kaimakamis E, Voutsas V, et al. An observational study on factors associated with ICU mortality in Covid-19 patients and critical review of the literature. *Sci Rep.* 2023;13:7804. [doi:10.1038/s41598-023-34613-x](https://doi.org/10.1038/s41598-023-34613-x)
32. Tongseengkee N, Surasombatpattana S, Tanomkiat W, et al. Characteristics, outcomes, and factors affecting mortality in hospitalized patients with CAP due to different variants of SARS-CoV-2 and non-COVID-19 CAP. *J Clin Med.* 2023;12:1388. [doi:10.3390/jcm12041388](https://doi.org/10.3390/jcm12041388)
33. Grieco DL, Bongiovanni F, Chen L, et al. Respiratory physiology of COVID-19-induced respiratory failure compared to ARDS of other etiologies. *Crit Care.* 2020;24:52. [doi:10.1186/s13054-020-03253-2](https://doi.org/10.1186/s13054-020-03253-2)
34. Beloncle F, Studer A, Seegers V, et al. Longitudinal changes in compliance, oxygenation and ventilatory ratio in COVID-19 versus non-COVID-19 pulmonary acute respiratory distress syndrome. *Crit Care.* 2021;25:248. [doi:10.1186/s13054-021-03665-8](https://doi.org/10.1186/s13054-021-03665-8)
35. Ionescu F, Zimmer MS, Petrescu I, et al. Extubation Failure in Critically Ill COVID-19 Patients: Risk factors and impact on in-hospital mortality. *J Int Care Med.* 2021;36:1018-1024. [doi:10.1177/08850666211020281](https://doi.org/10.1177/08850666211020281)
36. Halaseh RM, Drescher GS, Al-Ahmad M, et al. Risk factors and outcomes Associated with re-intubation secondary to respiratory failure in patients with COVID-19 ARDS. *Respir Care.* 2023;69(1):50-60. [doi:10.4187/respcare.10881](https://doi.org/10.4187/respcare.10881)
37. Riera J, Barbeta E, Tormos A, et al. Effects of intubation timing in patients with COVID-19 throughout the four waves of the pandemic: a matched analysis. *Eur Respir J.* 2023;61:2201426. [doi:10.1183/13993003.01426-2022](https://doi.org/10.1183/13993003.01426-2022)
38. Tomazini BM, Costa ELV, Besen BAMP, et al. Clinical outcomes and lung mechanics characteristics between COVID-19 and non-COVID-19-associated acute respiratory distress syndrome: a propensity score analysis of two major randomized trials. *Rev Bras Ter Int.* 2022;34:335-341. [doi:10.5935/0103-507X.20220040-pt](https://doi.org/10.5935/0103-507X.20220040-pt)
39. Nolley EP, Sahetya SK, Hochberg CH, et al. Outcomes among mechanically ventilated patients with severe pneumonia and acute hypoxemic respiratory failure from SARS-CoV-2 and other etiologies. *JAMA Net Open.* 2023;6:e2250401. [doi:10.1001/jamanetworkopen.2022.50401](https://doi.org/10.1001/jamanetworkopen.2022.50401)



40. Habashi NM, Camporota L, Gatto LA, et al. Functional pathophysiology of SARS-CoV-2-induced acute lung injury and clinical implications. *J Appl Physiol (1985)*. 2021;130:877-891. doi:10.1152/jappphysiol.00742.2020
41. Carvalho EV, Pinto SPS, Gomes EP, et al. Adherence to protective mechanical ventilation in COVID-19 versus non-COVID-19-associated acute respiratory distress syndrome: Comparison between two prospective cohorts. *Med Int (Engl Ed)*. 2023;47:445-453. doi:10.1016/j.medine.2023.01.004
42. Ghiani A, Tsitouras K, Paderewska J, et al. Ventilatory ratio and mechanical power in prolonged mechanically ventilated COVID-19 patients versus respiratory failures of other etiologies. *Thorax*. 2023;77:1753-1757. doi:10.1136/thorax-2023-024744
43. Bertelli M, Fusina F, Prezioso C, et al. COVID-19 ARDS is characterized by increased dead space ventilation compared with non-COVID ARDS. *Respir Care*. 2021;66:1406-1415. doi:10.4187/respcare.08786
44. Bhatraju PK, Morrell ED, Zelnick L, et al. Comparison of host endothelial, epithelial and inflammatory response in ICU patients with and without COVID-19: a prospective observational cohort study. *Crit Care*. 2021;25:148. doi:10.1186/s13054-021-03547-z
45. Camporota L, Chiumello D, Busana M, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome. *Lancet Respir Med*. 2021;9:e1. doi:10.1016/S2213-2600(20)30505-1
46. Shi R, Lai C, Teboul JL, et al. COVID-19 ARDS is characterized by higher extravascular lung water than non-COVID-19 ARDS: The PiCCOVID study. *Crit Care*. 2021;25:186. doi:10.1186/s13054-021-03594-6
47. Barbeta E, Benegas M, Sánchez M, et al. Risk factors and clinical impact of fibrotic-like changes and the organizing pneumonia pattern in patients with COVID-19- and non-COVID-19-induced acute respiratory distress syndrome. *Arch Bronconeumol*. 2022;58:183-187. doi:10.1016/j.arbres.2021.05.023
48. Raimondi F, Novelli L, Ghirardi A, et al. Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study. *BMC Pulmonary Med*. 2021;21:96. doi:10.1186/s12890-021-01455-0
49. Chiumello D, Modafferi L, Fratti I. Risk factors and mortality in elderly ARDS COVID-19 compared to patients without COVID-19. *J Clin Med*. 2022;11:5180. doi:10.3390/jcm11175180

## SUPPLEMENTARY MATERIALS

### Supplementary Table 1

Download: <https://cjrt.ca/article/122402-survival-analysis-of-covid-19-versus-non-covid-19-patients-requiring-intensive-care-for-acute-respiratory-distress-syndrome-an-observational-retrospe/attachment/241137.pdf>

---